Rakovina Therapeutics Inc. (RKV.V)
| Previous Close | 0.0850 |
| Open | 0.0900 |
| Bid | 0.0850 x N/A |
| Ask | 0.0900 x N/A |
| Day's Range | 0.0900 - 0.0900 |
| 52 Week Range | 0.0050 - 0.1600 |
| Volume | |
| Avg. Volume | 74,204 |
| Market Cap | 6.285M |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | May 29, 2024 - Jun 03, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireRakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, April 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and provided a corporate update. 2023 Highlights and Recent Developments On March 27, 2024 we announced a collaboration agreement with Dr. Artem Cherkasov granting R
- GlobeNewswire
Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today
VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response inhibitor therapeutics, is pleased to announce that members of the Company’s scientific team presented new data on the Company’s novel kt-3000 series at the American Association of Cancer Research (AACR) Annual Meeting at the San D
- Baystreet
Stocks in play: Rakovina Therapeutics Inc.
Will be hosting an informational webinar on Wednesday, April 3. Rakovina Therapeutics Inc. shares V.RKV ...
